News | September 25, 2022
Aptar Pharma collaborates with Fluidda
The companies will leverage their respective proprietary technology platforms
The companies will leverage their respective proprietary technology platforms
The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
Lutio has the potential to offer significant cost savings when available to UK patients.
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Subscribe To Our Newsletter & Stay Updated
